Meningococcal bivalent vaccine group B OMV - Finlay/GlaxoSmithKline

Drug Profile

Meningococcal bivalent vaccine group B OMV - Finlay/GlaxoSmithKline

Alternative Names: Bivalent MenB OMV vaccine - Finlay/GlaxoSmithKline

Latest Information Update: 18 Sep 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Finlay Institute of Cuba; GlaxoSmithKline Biologicals
  • Class Meningococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Meningococcal group B infections

Most Recent Events

No Data Available
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top